Thank you, Douglas. Good morning and welcome everyone also on my behalf. We will start today with quarter one highlights and a couple of comments on the operating environment and market. And then I will end my part with a review of the segments. And after this, Tomas will take over, take you through the financials before we continue with the Q&A. To begin with, I believe that we can say that we had a good start to the year. In quarter one, the sales grew by 4% to €375 million. This was driven by both distribution and wholesale segments. Usually, here we would comment on the constant currency figures, but in quarter one, the Swedish krona did not cause any significant head or tailwind year on year. So we will focus on the reported figures. Also, profitability improved in quarter one. Adjusted EBIT, when excluding the loss from the Swedish dose dispensing business, improved by 14% to €4.5 million, while the reported adjusted EBIT was 4 million. The improvement in profitability was supported by lower operating expenses and freight costs. A brief comment about the refined strategy that we launched at the end of last year. The implementation is progressing well and a key milestone was, of course, the announcement of the ERP and warehouse management investments in January. This project is well up to speed and proceeding according to plan. But I also wanted to comment that we are focusing a lot this year on engaging with our senior management. This is an essential part of rolling out the strategy so that we ensure alignment and strengthen our common understanding of our priorities, but also importantly, develop our leadership. And then finally, a couple of comments on the joint venture company Kronans Apotek. Apotekstjänst Sverige AB. In quarter one, e-commerce continued to grow steadily while the customer flow in the brick-and-mortar pharmacies was weaker year on year, which resulted in reduced volumes, market share, and adjusted EBIT. And you might have seen last week that we announced regarding Kronans Apotek. But let me recap if you haven't seen it. Last week, Kronans Apotek got a new CEO. The previous CEO, Tomas Rupšys, did an important job with the integration of Kronans Apotek and Apotekstjänst Sverige AB. But now it's time for the company to go into the next phase of its development. Kronans Apotek will continue to develop its customer experience and end product range, both in physical and digital stores. The focus remains on long-term profitability improvement, integration activities, and business development. For this role, the board has appointed Tomas Rupšys, who has vast experience in retail and fast-moving consumer goods both in the UK and in Ireland, and he has also been the CEO of Maxima, the biggest retail chain in Lithuania. When looking at the overall operating environment, we saw slight stabilization compared with last year. Cost inflation has slowed down, and energy prices have been stabilizing while we saw fluctuations in the fuel prices. Although the consumer confidence indicators, both in Sweden and in Finland, have slightly improved from the earlier significant drop. They have still been below historical averages. So all in all, consumer confidence is still weak. The pharmaceutical distribution market continued at a steady growth in quarter one. Still, the challenges in the availability of pharmaceuticals have continued in Europe. Since we now have two new reporting segments, we also want to provide some additional market information relating to the wholesale segment. But first, if we look at the pharmaceutical distribution market, we saw that the market value in Sweden grew by 7% in the first quarter and by 4% in Finland. Our market shares were stable year on year, with a share of 42% in Sweden and 45% in Finland. In the Finnish dose dispensing business, we had a market share of 29%. With regards to the consumer health market, we want to give you some indication of market size and growth. While we will not comment on the market development on a quarterly basis based on external market data, the value of the market is estimated at around €1.5 billion. The historical growth has been about 3%, and that is expected to continue, although with significant differences between the categories. In Sweden, for example, products such as vitamins, dietary supplements, and sports nutrition are expected to see increased demand, while in Finland consumers are expected to demand more natural and clean products with high-quality ingredients and available in easy-to-use formats. And then before I dive into the segments, I want to make a brief reminder of what the segments include. We changed the reporting at the beginning of this year so that we can be more transparent and also give better visibility into our businesses. The distribution segment consists of pharmaceutical, logistics, and dose dispensing services. This is the largest segment that we have with an annual net sales of €1.2 billion, which equals about 79% of the group net sales. The wholesale segment consists of the wholesale of traded goods and over-the-counter or OTC products, parallel import, and special licensed medicines, as well as advisory services. The annual net sales of the segment are about €306 million. The wholesale business is a bit more profitable because of the type of products and services that we sell in this segment, and that is also what you can see in this picture. Next, I will discuss the segments in quarter one and also start off with the dose dispensing segment. In quarter one, the net sales grew by 4% to €294 million. This was largely driven by steady market growth. Profitability improved by 29%, with adjusted EBIT increasing to €4.1 million. When we exclude losses from the Swedish dose dispensing business, adjusted EBIT was €4.6 million, which is €1 million above quarter one last year. Profitability improvement was important, supported by a lower cost base compared with the previous year. Freight costs were lower thanks to operational improvements, and lower fuel prices, and operating expenses were lower due to cost reductions in the Swedish dose dispensing business. In the distribution business, we focus on our core and continue to build on the good development we saw last year. In quarter one, our market shares were stable year on year, as you saw earlier, and we have gained new customers and renewed important distribution contracts to support our growth going forward. Then looking at the wholesale segments. In quarter one, the net sales grew by 5% to €81 million. We saw solid growth in the Swedish wholesale business and also good development in advisory services. Profitability, on the other hand, declined slightly from €3 million to €2.8 million. The decline was related to low volumes in the Finnish wholesale business. Going back to our refined strategy, growing the wholesale business is one of the three strategic goals that we have in the strategy. In the long term, we want to grow the business by developing our brand portfolio and product categories. And this is something that will take some time. During the start of this year, our focus has been on building our offering and technical capabilities to better meet the needs of our growing customer segments. In addition, we have made appointments in key leadership positions, so really building a solid foundation for growth is what we have started to do. Now, Tomas, let's go over to you and look at the financials.